Norvaline

Norvaline

SCHEMBL166373

CCCC(N)C(=O)O.O=[N+]([O-])OCCO[N+](=O)[O-].OCCO

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A2 P43004 4/20 0.41
SLC1A1 P43005 4/20 0.41
GRIK1 P39086 4/20 0.41
GRIK2 Q13002 4/20 0.41
SLC1A3 P43003 3/20 0.41
NOS1 P29475 5/20 0.41
PMP22 Q01453 2/20 0.38
NOS3 P29474 2/20 0.36
NOS2 P35228 2/20 0.36
GSR P00390 2/20 0.35
GRM8 O00222 1/20 0.35
GRM6 O15303 1/20 0.35
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
CYP1A2 P05177 1/20 0.35
GRM5 P41594 1/20 0.35
GRIA1 P42261 1/20 0.35
GRIA2 P42262 1/20 0.35
GRIA3 P42263 1/20 0.35
GRIA4 P48058 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Norvaline SCHEMBL167816 0.94 NOS1 (0.42) SLC1A2SLC1A1GRIK1GRIK2SLC1A3
Norvaline SCHEMBL166375 0.85 SLC1A2 (0.47) SLC1A2SLC1A1GRIK1GRIK2SLC1A3
SCHEMBL456815 0.81 NOS1 (0.45) SLC1A2SLC1A1GRIK1GRIK2SLC1A3
SCHEMBL166023 0.81 PTGS2 (0.39) SLC1A2SLC1A1GRIK1GRIK2SLC1A3
SCHEMBL166321 0.81 PTGS2 (0.39) SLC1A2SLC1A1GRIK1GRIK2SLC1A3
Norvaline SCHEMBL2513624 0.79 SLC1A2 (0.52) SLC1A2SLC1A1GRIK1GRIK2SLC1A3
Norvaline SCHEMBL2512779 0.79 SLC1A2 (0.52) SLC1A2SLC1A1GRIK1GRIK2SLC1A3
Norvaline SCHEMBL2512780 0.79 SLC1A2 (0.52) SLC1A2SLC1A1GRIK1GRIK2SLC1A3
Norvaline SCHEMBL2513626 0.79 SLC1A2 (0.52) SLC1A2SLC1A1GRIK1GRIK2SLC1A3
Norvaline SCHEMBL2517586 0.79 SLC1A2 (0.52) SLC1A2SLC1A1GRIK1GRIK2SLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170105959-A1 COMPOSITIONS CONTAINING NITRIC OXIDE AMINO ACID ESTERS AND METHODS FOR IMPROVING SEXUAL PERFORMANCE SMARTEK INTERNATIONAL, INC. 2017-04-20 US disclosed
WO-2012027827-A1 NITRIC OXIDE AMINO ACID ESTERS FOR SKIN REJUVENATION ORAL DELIVERY TECHNOLOGY LTD. (CA) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170105959-A1 COMPOSITIONS CONTAINING NITRIC OXIDE AMINO ACID ESTERS AND METHODS FOR IMPROVING SEXUAL PERFORMANCE NOS1, NOS2, NOS3 SLC1A2 80/4885SLC1A1 99/4885GRIK1 2488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.